Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial.

被引：0

作者：

Karimi, Yasmin

Ghesquieres, Herve

Jurczak, Wojciech

Cheah, Chan

Clausen, Michael

Lugtenburg, Pieternella

Cunningham, David

Do, Young Rok

Lewis, David John

Gasiorowski, Robin

Kim, Tae Min

Van der Poel, Marjolein

Poon, Michelle Li Mei

Feldman, Tatyana A.

Linton, Kim M.

Sureda, Anna

Hutchings, Martin

Stirner, Mariana Cota

Sacchi, Mariana

Thieblemont, Catherine

机构：

[1] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI USA

[2] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Pierre Benite, France

[3] MSC Natl Res Inst Oncol, Krakow, Poland

[4] Sir Charles Gairdner Hosp, Nedlands, WA, Australia

[5] Vejle Hosp, Vejle, Denmark

[6] Univ Med Ctr, Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands

[7] Royal Marsden NHS Fdn Trust, Sutton, England

[8] Keimyung Univ, Dongsan Med Ctr, Daegu, South Korea

[9] Univ Hosp Plymouth NHS Trust, Derriford Hosp, Plymouth, England

[10] Univ Sydney, Concord Hosp, Sydney, NSW, Australia

[11] Seoul Natl Univ Hosp, Seoul, South Korea

[12] Maastricht Univ, Med Ctr, Maastricht Dept Internal Med, Div Hematol GROW,Sch Oncol & Dev Biol, Maastricht, Netherlands

[13] Natl Univ Singapore Hosp, Singapore, Singapore

[14] Hackensack Univ, Hackensack Meridian Hlth, Med Ctr, Hackensack, NJ USA

[15] Christie NHS Fdn Trust, Manchester, England

[16] Manchester Canc Res Ctr, Manchester, England

[17] Univ Barcelona, Inst Catal Oncol, Hosp Duran & Reynals, IDIBELL,Hosp Llobregat, Barcelona, Spain

[18] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark

[19] AbbVie Inc, N Chicago, IL USA

[20] Genmab, Princeton, NJ USA

[21] Univ Paris, Hop St Louis, Assistance Publ & Hop Paris APHP, Hematooncol, Paris, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7525

引用

页数：1

共 50 条

[41] Epcoritamab SC plus R-Mini-CHOP Leads to High Complete Metabolic Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: First Disclosure from Arm 8 of the Epcore NHL-2 Trial
Vermaat, Joost S. P.
Brody, Joshua
Duras, Juraj
Karimi, Yasmin H.
Cheah, Chan Y.
Darrah, Justin M.
Musuraca, Gerardo
Morschhauser, Franck
Hoehn, Daniela
Rana, Ali
Song, Yaou
Jafarinasabian, Pegah
Belada, David
BLOOD, 2023, 142
[42] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
Oluwole, Olalekan O.
Forcade, Edouard
Munoz, Javier
de Guibert, Sophie
Vose, Julie M.
Bartlett, Nancy L.
Lin, Yi
Deol, Abhinav
McSweeney, Peter A.
Goy, Andre H.
Kersten, Marie Jose
Jacobson, Caron A.
Farooq, Umar
Minnema, Monique C.
Thieblemont, Catherine
Timmerman, John
Stiff, Patrick
Avivi, Irit
Tzachanis, Dimitrios
Zheng, Yan
Vardhanabhuti, Saran
Nater, Jenny
Shen, Rhine R.
Miao, Harry
Kim, Jenny
van Meerten, Tom
BLOOD, 2022, 140 : 10399 - 10401
[43] Multicenter Phase II Trial Addressing Lenalidomide Maintenance in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Lligible for Autologous Stem Cell Transplantation (ASCT): Efficacy and Safety Results after a Median Follow-up of Five Years
Ferreri, Andres J. M.
Sassone, Marianna
Zaja, Francesco
Re, Alessandro
Spina, Michele
Di Rocco, Alice
Fabbri, Alberto
Angelillo, Piera
Stelitano, Caterina
Frezzato, Maurizio
Rusconi, Chiara
Zambello, Renato
Arcari, Annalisa
Bertoldero, Giovanni
De Lorenzo, Daniela
Scarano, Eloise
Volpetti, Stefano
Perrone, Salvatore
Calimeri, Teresa
Cecchetti, Caterina
Ciceri, Fabio
Ponzoni, Maurilio
BLOOD, 2018, 132
[44] CD20-Tcb (RG6026), a Novel "2:1" Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Phase I First in Human Trial
Hutchings, Martin
Iacoboni, Gloria
Morschhauser, Franck
Offner, Fritz
Sureda, Anna
Salles, Gilles Andre
Carlo-Stella, Carmelo
Martinez Lopez, Joaquin
Thomas, Denise
Morcos, Peter N.
Quackenbush, Betsy
Ferlini, Cristiano
Bacac, Marina
Broeske, Ann-Marie E.
Dimier, Natalie
Moore, Tom
Weisser, Martin
Dickinson, Michael
BLOOD, 2018, 132
[45] C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up
Li, Ping
Yu, Wen-Juan
Zhou, Lili
Yang, Min
Ye, Shiguang
Zhu, Judy
Huang, Jiaqi
Zhang, Yan
Li, Lanfang
Zhao, Jing
Zhu, Kevin
Li, Jing
Zheng, Chengxiao
Lan, Liping
Wan, Hui
Yao, Yihong
Zhang, Huilai
Zhou, Daobin
Jin, Jie
Liang, Aibin
BLOOD, 2023, 142
[46] A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial
Hu, Boyu
Nastoupil, Loretta J.
Holmes, Houston
Hamdan, Ayad
Kanate, Abraham
Farooq, Umar
Cherry, Mohamad
Brem, Elizabeth
Pinter-Brown, Lauren C.
Ermann, Daniel Arthur
Husnain, Muhammad
Micklethwaite, Kenneth
Rizvi, Syed
Hammad, Ashley
Thompson, Ben
Zudaire, Enrique
Portella, Socorro
Hamadani, Mehdi
Essell, James
O'Brien, Susan Mary
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[47] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/ Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)
Oluwole, Olalekan O.
Forcade, Edouard
Muñoz, Javier
de Guibert, Sophie
Vose, Julie M.
Bartlett, Nancy L.
Lin, Yi
Deol, Abhinav
McSweeney, Peter A.
Goy, Andre H.
Kersten, Marie Jose
Jacobson, Caron
Farooq, Umar
Minnema, Monique C.
Thieblemont, Catherine
Timmerman, John M.
Stiff, Patrick
Avivi, Irit
Tzachanis, Dimitrios
Kim, Jenny J.
Zheng, Yan
Shen, Rhine R.
Vardhanabhuti, Saran
Van Meerten, Tom
BLOOD, 2021, 138
[48] CC-90010, a reversible, potent oral bromodomain and extraterminal inhibitor (BETi) in patients (pts) with advanced solid tumours (aSTs) and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Longer follow-up from parts A & B and first reporting of part C of a phase I study
Moreno, V.
Vieito Villar, M.
Sepulveda Sanchez, J. M.
Galvao, V.
Hernandez Guerrero, T.
Doger, B.
Saavedra, O.
Carlo Stella, C.
Michot, J-M.
Italiano, A.
Magagnoli, M.
Carpio, C.
Sarmiento, R.
Amoroso, B.
Aronchik, I.
Filvaroff, E.
Hanna, B.
Pinto, A.
Nikolova, Z.
Brana, I.
ANNALS OF ONCOLOGY, 2021, 32 : S5 - S5
[49] Two-Year Follow-up Results of C-CAR066, a Novel Anti-CD20 Chimeric Antigen Receptor Cell Therapy (CAR-T) in Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) Patients after Failure of CD19 CAR-T Therapy
Li, Ping
Liu, Wei
Ye, Shiguang
Zhou, Lili
Zhu, Judy
Huang, Jiaqi
Li, Jing
Zhu, Shigui
Zheng, Chengxiao
Zhu, Kevin
Yao, Xin
Wan, Hui
Yao, Yihong
Liang, Aibin
Zou, Dehui
BLOOD, 2023, 142
[50] Glofitamab Plus R-CHOP Induces High Response Rates with Minimal Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) NonHodgkin Lymphoma (NHL) and Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results from a Dose-Escalation and Safety Run-in Phase Ib Study
Ghosh, Nilanjan
Townsend, William
Dickinson, Michael
Topp, Max
Tani, Monica
Santoro, Armando
Crump, Michael
Morschhauser, Franck
Le Gouill, Steven
Mehta, Amitkumar
Panchal, Anesh
Wu, Chun
Barrett, Martin
Humphrey, Kathryn
Qayum, Naseer
Hutchings, Martin
BLOOD, 2021, 138

← 1 2 3 4 5 →